Researchers map genetic mutation behind incurable disease

Researchers at Karolinska Institutet have mapped the genetic mutation behind the incurable disease systemic mastocytosis. The results give insights into the origin of the disease, and the researchers also discovered a protein with potential to improve disease diagnosis. The results are published in the journal EBioMedicine.

Systemic mastocytosis is an incurable disease characterized by accumulation of mast cells, a type of immune cell. Mild disease forms often cause severe allergy-like symptoms, whereas the advanced form, mast cell leukemia, leads to complete organ failure and death. A common feature in most of the patients is a mutation in a gene called KIT.

Researchers at Karolinska Institutet and Uppsala University have now traced which cells in the body that harbor the KIT mutation.

Map of the mutation's propagation

Analyzing more than 10,000 bone marrow cells allowed the researchers to generate a map of the mutation's propagation.

"The mutation could be traced all the way back to the blood stem cell in some patients," says Joakim Dahlin, researcher at Karolinska Institutet's Department of Medicine in Solna, and principal investigator of the study. "It was also obvious that the mutated mast cells outcompete the normal mast cells in the patients."

An incidental finding was also that mast cells in patients expressed extreme levels of a protein called CD45RA.

"There was a large difference in protein levels between patients and the control group," says Jennine Grootens, PhD student at the same department and first author of the study. "We are now investigating if we can use this protein to diagnose systemic mastocytosis."

Insights into the origin of the disease

According to the researchers, the study provides deep insights into the origin of the disease. They also note that the presence of mutated blood stem cells could explain why the disease is difficult to cure.

The study is a result of a collaborative effort between scientists and physicians at the Centers of Excellence in Mastocytosis in Stockholm and Uppsala.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Causal variant-targeted ribonucleic acid treatment for congenital melanocytic nevi